ClinicalTrials.gg
RecruitingNCT07019896MVS-ERMUpdated Jun 13, 2025

Minimal Vitrectomy Surgery for Epiretinal Membrane

An interventional study of Minimal Vitrectomy Surgery and Conventional Vitrectomy in Epiretinal Membrane, Macular Edema (ME) and Nuclear Cataract, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2024, registered Jun 2025).
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter randomized controlled trial evaluates Minimal Vitrectomy Surgery (MVS) versus conventional vitrectomy for idiopathic epiretinal membrane (ERM). The primary endpoints include visual acuity improvement and cataract progression after 12 months. MVS aims to minimize vitreous removal while ensuring complete membrane removal through adaptive limited vitrectomy.

Read the detailed description

Idiopathic epiretinal membrane (ERM) is characterized by fibrocellular proliferation on the retinal surface, leading to macular edema, metamorphopsia, and visual impairment. Traditional treatment involves pars plana vitrectomy (PPV) with posterior vitreous detachment (PVD) induction and core vitrectomy, which may increase the risk of postoperative cataract.

Minimal Vitrectomy Surgery (MVS) is a modified surgical approach designed to minimize vitreous removal and preserve the hyaloid. The epiretinal membrane is directly peeled through the intact vitreous. If pre-existing vitreous floaters or membrane fragments remain after peeling and cannot be removed safely with micro-forceps, limited localized vitrectomy is selectively performed to eliminate these floaters and avoid postoperative visual disturbances.

This trial aims to evaluate the efficacy and safety of MVS compared to conventional vitrectomy, focusing on visual improvement, macular thickness, cataract progression, ERM recurrence, and intraoperative complications.

02

Conditions studied

  • Epiretinal Membrane
  • Macular Edema (ME)
  • Nuclear Cataract

Keywords

  • Idiopathic Epiretinal Membrane (ERM)
  • Minimal Vitrectomy Surgery (MVS)
  • Nonvitrectomizing Vitreous Surgery (NVS)
  • pars plana Vitrectomy (PPV)
03

In context

Epiretinal Membrane

130 studies on the registry are indexed under Epiretinal Membrane; 18 are open to participants now.

This study's planned enrollment of 140 is above the median of 51 across 79 interventional studies indexed under Epiretinal Membrane.

Browse Epiretinal Membrane studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging.
  3. Clear ocular media allowing adequate fundus imaging.
  4. Phakic eye.
  5. Ability and willingness to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion).
  2. Systemic conditions preventing safe surgery or follow-up.
  3. History of prior ocular or periocular use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Minimal Vitrectomy Surgery (MVS)

    The epiretinal membrane is peeled directly through the intact vitreous. Limited vitrectomy is selectively performed if pre-existing floaters or membrane fragments remain after peeling and cannot be removed safely with forceps.

    Procedure: Minimal Vitrectomy Surgery

  • Active comparator
    Conventional Vitrectomy (PPV)

    Standard pars plana vitrectomy is performed. Posterior vitreous detachment induction and core vitreous removal are conducted before membrane peeling.

    Procedure: Conventional Vitrectomy

Interventions

  • ProcedureMinimal Vitrectomy Surgery

    The epiretinal membrane is peeled directly through the intact vitreous. Limited localized vitrectomy is selectively performed if pre-existing floaters or membrane fragments remain after peeling.

  • ProcedureConventional Vitrectomy

    Standard pars plana vitrectomy is performed with posterior vitreous detachment induction and core vitreous removal prior to epiretinal membrane peeling.

06

What researchers measure

Primary outcomes

  1. Cataract progression assessed by LOCS III and DLI

    Cataract progression evaluated by Lens Opacities Classification System III (LOCS III) grading and Dysfunctional Lens Index (DLI) changes.

    Time frame: Baseline, 12 months

Secondary outcomes

  1. BCVA change from baseline to 12 months

    Change in best-corrected visual acuity (logMAR) from baseline to 12 months postoperatively.

    Time frame: Baseline, 1 week, 1 month, 3 months, 6 months, 12 months

  2. Change in central retinal thickness (CRT) by OCT

    Change in macular central retinal thickness as assessed by OCT.

    Time frame: Baseline, 1 week, 1 month, 3 months, 6 months, 12 months

  3. Epiretinal membrane recurrence rate

    Recurrence of epiretinal membrane at 12-month follow-up.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to patient privacy protection and the absence of participant consent for data sharing. The study data will be used exclusively for internal research purposes and regulatory submissions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

Of 30 interventional studies with no phase under Epiretinal Membrane, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 90. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Dec 1, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019896
Collaborators
Peking Union Medical College
Responsible party
Weihong Yu (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Jun 13, 2025
Start date
Dec 1, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jun 13, 2025

Study contacts

Weihong Yu, MD
Contact
yuweihongpumch@163.com
+8613671214306
Xufeng Zhao
Contact
yezhong019@163.com
+8619121036553
Weihong Yu, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion